Related Experiment Video
Updated: May 12, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Experimental System Design and Modelling of EGFR Extracellular Domain and Its Mutant Binding to Antibody Interacting
Feyzanur Erdemir1, Bertan Koray Balcioglu2, Tugba Arzu Ozal Ildeniz3
1Department of Biomedical Engineering, Institute of Natural Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, Türkiye.
Abstract:
The EGFR pathway is activated by ligand binding, and EGFR overexpression is linked to malignancies like colorectal and head and neck cancer. This pathway is targeted by monoclonal antibodies such as Cetuximab; however, drug resistance can arise, frequently because of EGFR gene alterations like mutation, particularly in domain III, which inhibits Cetuximab binding. EGFR and MEGFR (R497K mutated EGFR) plasmids were transfected into Chinese hamster ovary (CHO) cells, which do not express EGFR. Real-time PCR was performed using probes that were specifically developed for the R497K mutation. Furthermore, Cetuximab binding to EGFR and MEGFR was examined using molecular modeling. According to molecular modeling, the R497K mutation modifies the domain III structure, which lowers the binding affinity of Cetuximab. Curiously, Cetuximab also showed binding to MEGFR's domain IV. Real-time PCR showed that the probes specifically identified MEGFR in transfected CHO cells. The R497K mutation may result in treatment resistance by decreasing Cetuximab binding or increasing competitive ligand binding. Therefore, for individualized treatment, it is essential to find EGFR mutations in patient tumor samples. The R497K mutation may be successfully detected by the designed oligonucleotide probes, allowing for the early identification of potential resistance and directing the development of suitable treatment strategies.
Insights
A specific EGFR mutation (R497K) can cause resistance to Cetuximab cancer therapy by altering drug binding. New probes can detect this mutation, aiding personalized cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- The Epidermal Growth Factor Receptor (EGFR) pathway is crucial in cell growth and is often dysregulated in cancers like colorectal and head and neck cancer.
- Monoclonal antibodies, such as Cetuximab, target the EGFR pathway but can face challenges due to drug resistance.
- EGFR gene alterations, particularly mutations in domain III, are a common cause of resistance by inhibiting Cetuximab binding.
Purpose of the Study:
- To investigate the impact of the R497K mutation in EGFR on Cetuximab binding.
- To develop and validate oligonucleotide probes for detecting the R497K mutation.
- To explore potential resistance mechanisms and implications for personalized cancer therapy.
Main Methods:
- Transfection of Chinese hamster ovary (CHO) cells with EGFR and MEGFR (R497K mutated EGFR) plasmids.
- Development of specific real-time PCR probes for the R497K mutation.
- Molecular modeling to assess Cetuximab binding affinity to wild-type EGFR, mutated MEGFR, and their domains.
Main Results:
- Molecular modeling indicated that the R497K mutation alters EGFR domain III structure, reducing Cetuximab binding affinity.
- Cetuximab also demonstrated binding to MEGFR's domain IV.
- Real-time PCR confirmed that the designed probes specifically identified MEGFR in transfected cells.
Conclusions:
- The R497K EGFR mutation may lead to Cetuximab resistance by decreasing drug binding or increasing competitive ligand binding.
- Early detection of EGFR mutations like R497K is vital for guiding individualized cancer treatment.
- The developed oligonucleotide probes offer a method for identifying potential resistance, enabling timely adjustments to treatment strategies.
